Lenvervimab

Lenvervimab (INN;[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.[2]

Lenvervimab
Monoclonal antibody
Type?
SourceHumanized
Targethepatitis B virus surface antigen
Clinical data
Other namesGC1102
ATC code
  • none
Identifiers
CAS Number
UNII

This drug is being developed by GC Pharma. As of 2018, lenvervimab is undergoing Phase II/III trials.

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.